[Phoenix, AZ, May 1, 2017]—Paradigm Diagnostics, a molecular information & Next Generation Sequencing corporation specializing in providing cancer testing for patients with cancer, today announced that it has entered into a contractual agreement with AHCCCS for coverage of Paradigm Cancer Diagnostic (PCDxTM).
Brian Wright, VP of Commercial Development and Marketing at Paradigm, noted, “Ensuring patients in Arizona fighting cancer have equal access to Paradigm PCDx is important to us. Through this contract, a significant number of patients and their treating clinicians will now have improved access to our leading oncology testing service and the opportunity to benefit from personalized cancer care.”
PCDx is a comprehensive clinical-grade comprehensive sequencing test that is designed to provide physicians and patients with a targeted and personalized approach to cancer treatment by identifying underlying genomic and proteomic abnormalities in a tumor’s DNA, RNA & Protein. The test interrogates the most relevant genomic targets with a 5,000x average depth of coverage with 72 therapeutic associations. Results are typically delivered in 4-5 business days.
The Arizona Health Care Cost Containment Systems or (AHCCCS) is Arizona’s Medicaid program and provides coverage and care for more than 1.9 million individuals and families.
Paradigm Diagnostics offers accurate, comprehensive and clinically actionable cancer genomic profiling and therapeutic information in 4-5 business days to better support patient care. The Paradigm Cancer Diagnostic (PCDx) comprehensive sequencing test analyzes DNA, RNA, and Protein by immunohistochemisty to provide treating physicians and patients with more precise information about the specific cancer pathways in the tumor to allow for more effective decision-making. For more information visit http://www.paradigmdx.com or visit us on Twitter @Paradigm_DX